How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Sell
48
HIMS Quote, Financials, Valuation and Earnings
Last price:
$26.62
Seasonality move
:
21.09%
Day range:
$25.06 - $26.76
52-week range:
$8.09 - $35.02
Dividend yield:
0%
P/E ratio:
60.52x
P/S ratio:
4.88x
P/B ratio:
13.22x
Volume:
7.2M
Avg. volume:
14.9M
1-year change:
194.25%
Market cap:
$5.8B
Revenue:
$872M
EPS (TTM):
$0.44
Analysts' Opinion
-
Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $25.21, Hims & Hers Health has an estimated downside of -5.33% from its current price of $26.63.
-
Price Target UpsideAccording to analysts, the highest upside price target is $38.00 representing 42.7% upside increase from its current price of $26.63.
Fair Value
-
According to the consensus of 9 analysts, Hims & Hers Health has -5.33% downside to fair value with a price target of $25.21 per share.
HIMS vs. S&P 500
-
Over the past 5 trading days, Hims & Hers Health has underperformed the S&P 500 by -6.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hims & Hers Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hims & Hers Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hims & Hers Health reported revenues of $401.6M.
Earnings Growth
-
Hims & Hers Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hims & Hers Health reported earnings per share of $0.32.
Enterprise value:
5.6B
EV / Invested capital:
--
Price / LTM sales:
4.88x
EV / EBIT:
129.68x
EV / Revenue:
4.48x
PEG ratio (5yr expected):
--
EV / Free cash flow:
37.19x
Price / Operating cash flow:
40.53x
Enterprise value / EBITDA:
98.32x
Gross Profit (TTM):
$1B
Return On Assets:
21.22%
Net Income Margin (TTM):
8.15%
Return On Equity:
27.83%
Return On Invested Capital:
27.83%
Operating Margin:
5.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $444.4M | $792.6M | $1.2B | $226.7M | $401.6M | |
| Gross Profit | $338.5M | $643.2M | $1B | $187.3M | $317.9M | |
| Operating Income | -$78.7M | -$40.7M | $42.9M | -$8.6M | $22.4M | |
| EBITDA | -$71.6M | -$31.8M | $56.6M | -$6.2M | $26.8M | |
| Diluted EPS | -$0.42 | -$0.17 | $0.44 | -$0.04 | $0.32 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $107.1M | $274.2M | $233.5M | $250.2M | $326.4M | |
| Total Assets | $119.2M | $420.1M | $382.8M | $413.9M | $602.3M | |
| Current Liabilities | $17M | $52.5M | $66.8M | $82.5M | $152.6M | |
| Total Liabilities | $262.5M | $64.9M | $71.9M | $85.3M | $162.2M | |
| Total Equity | -$143.3M | $355.2M | $310.9M | $328.6M | $440.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.9M | $44.8M | $186.7M | $25.2M | $85.3M | |
| Cash From Investing | $38.9M | -$26.8M | $18.9M | -$31.1M | -$10.4M | |
| Cash From Financing | -$22.7M | -$18M | -$98.2M | -$1.6M | -$38.8M | |
| Free Cash Flow | -$29M | $26.9M | $149.6M | $19.3M | $79.4M | |
HIMS
Sector
Market Cap
$5.8B
$49.2M
Price % of 52-Week High
76.04%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
2%
-0.74%
1-Year Price Total Return
194.25%
-30.94%
Beta (5-Year)
1.309
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$26.50
200-day SMA
Buy
Level
$19.69
Bollinger Bands (100)
Buy
Level
15.95 - 27.49
Chaikin Money Flow
Sell
Level
-21.4M
20-day SMA
Sell
Level
$28.75
Relative Strength Index (RSI14)
Sell
Level
47.68
ADX Line
Sell
Level
21.81
Williams %R
Neutral
Level
-72.093
50-day SMA
Buy
Level
$26.30
MACD (12, 26)
Sell
Level
-0.47
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-10.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.8017)
Buy
CA Score
(Annual)
Level (1.4881)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (0.0695)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Stock Forecast FAQ
In the current month, HIMS has received 2 Buy ratings 7 Hold ratings, and 0 Sell ratings. The HIMS average analyst price target in the past 3 months is $25.21.
-
Where Will Hims & Hers Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hims & Hers Health share price will drop to $25.21 per share over the next 12 months.
-
What Do Analysts Say About Hims & Hers Health?
Analysts are divided on their view about Hims & Hers Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hims & Hers Health is a Sell and believe this share price will rise from its current level to $18.00.
-
What Is Hims & Hers Health's Price Target?
The price target for Hims & Hers Health over the next 1-year time period is forecast to be $25.21 according to 9 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is HIMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hims & Hers Health is a Hold. 7 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HIMS?
You can purchase shares of Hims & Hers Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hims & Hers Health shares.
-
What Is The Hims & Hers Health Share Price Today?
Hims & Hers Health was last trading at $26.62 per share. This represents the most recent stock quote for Hims & Hers Health. Yesterday, Hims & Hers Health closed at $26.63 per share.
-
How To Buy Hims & Hers Health Stock Online?
In order to purchase Hims & Hers Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
